Combination Chemotherapy With Carboplatin, Docetaxel, and Gemcitabine in Advanced Non–Small-Cell Lung Cancer: A Phase II Study
| Autor: | A. Kalantaridou, A. Visvikis, A. Halikia, F. Antoniou, A. Athanassiou, S. Batzios, N. Karvounis, D.G. Pectasides, A. Aspropotamitis |
|---|---|
| Rok vydání: | 1999 |
| Předmět: |
Adult
Male Oncology Cancer Research medicine.medical_specialty Lung Neoplasms Paclitaxel medicine.medical_treatment Phases of clinical research Docetaxel Deoxycytidine Carboplatin chemistry.chemical_compound Carcinoma Non-Small-Cell Lung Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans Lung cancer Aged Chemotherapy Performance status business.industry Combination chemotherapy Middle Aged medicine.disease Gemcitabine Surgery Treatment Outcome chemistry Female Taxoids business medicine.drug |
| Zdroj: | Journal of Clinical Oncology. 17:3816-3821 |
| ISSN: | 1527-7755 0732-183X |
| DOI: | 10.1200/jco.1999.17.12.3816 |
| Popis: | PURPOSE: To evaluate the efficacy and toxicity of the combination of carboplatin, docetaxel, and gemcitabine in patients with advanced non–small-cell lung cancer (NSCLC). PATIENTS AND METHODS: Forty-five chemotherapy-naive patients with NSCLC were treated on an out-patient basis with carboplatin area under the curve 5 intravenous (IV) and gemcitabine 800 mg/m2 IV on day 1 and docetaxel 75 mg/m2 IV and gemcitabine 800 mg/m2 IV on day 8. Granulocyte colony-stimulating factor (150 ug/m2 subcutaneously) was given prophylactically from day 3 to day 6 and day 10 to day 16. Chemotherapy was repeated every 4 weeks. Patients were evaluated for response every two cycles of treatment. RESULTS: The median age of the patients was 58 years (range, 24 to 75 years). The performance status was 0 for 16 patients, 1 for 17 patients, and 2 for 12 patients. Nine patients (20%) had stage IIIB disease, and 36 (80%) had stage IV; histology was mainly squamous cell carcinoma (51.2% of patients) that was poorly differentiated (37.8%). All 45 patients were assessable for toxicity, and 41 were assessable for response. On an intent-to-treat analysis, the objective response rate was 46.5% (21 out of 45 patients; 95% confidence interval [CI], 31.7% to 62.5%). Of the 45 patients, four (8.8%) achieved a complete response (95% CI, 2.5% to 21.2%); 17 (37.7%) achieved a partial response (95% CI, 23.8% to 53.5%); seven (15.5%) had stable disease; and 14 (31.1%) had progressive disease. The median survival time was 13.5 months, and the actuarial 1-year survival rate was 51.11%. The median duration of response was 7.6 months, and the time to tumor progression was 8.1 months. Grade 3/4 anemia and thrombocytopenia occurred in 17.7% and 28.8% of patients, respectively. Twenty-one patients (46.6%) developed grade 3/4 neutropenia, and six patients (13.3%) were complicated with fever. Alopecia was universal. Grade 3 diarrhea occurred in four patients (8.8%); grade 3/4 neurotoxicity occurred in 10 patients (22.2%); and grade 2/3 allergic reaction occurred in three patients (16.6%). There were no treatment-related deaths. Six patients (13.3%) required a dose reduction, two of which required two reductions. CONCLUSIONS: The combination of carboplatin, docetaxel, and gemcitabine is an effective regimen for the treatment of chemotherapy-naive patients with advanced NSCLC, causing only moderate toxicity. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|